{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:49:23Z","timestamp":1761515363859,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.4158\/ep.12.2.231","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:38:00Z","timestamp":1365197880000},"page":"231-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thyrotoxicosis During Pegylated Interferon Therapy in a Patient With Chronic Hepatitis C Virus"],"prefix":"10.1016","volume":"12","author":[{"given":"Huy A.","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.12.2.231_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4158\/EP.11.2.135","article-title":"Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C","volume":"11","author":"Lin","year":"2005","journal-title":"Endocr Pract."},{"key":"10.4158\/EP.12.2.231_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon-alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid."},{"key":"10.4158\/EP.12.2.231_bb0015","series-title":"Werner & Ingbar\u2019s The Thyroid: A Fundamental and Clinical Text","first-page":"1044","article-title":"Infectious thyroiditis","author":"Farwell","year":"2000"},{"key":"10.4158\/EP.12.2.231_bb0020","series-title":"Williams Textbook of Endocrinology","first-page":"411","article-title":"Thyrotoxicosis","author":"Davies","year":"2003"},{"key":"10.4158\/EP.12.2.231_bb0025","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.2004-0627","article-title":"Clinical review 169: interferon-alpha-related thyroid disease; pathophysiological, epidemiological, and clinical aspects","volume":"89","author":"Carella","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.12.2.231_bb0030","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis [erratum in N Engl J Med. 2003;349:620]","volume":"348","author":"Pearce","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.12.2.231_bb0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2265.2002.01553.x","article-title":"Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis","volume":"56","author":"Wong","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.12.2.231_bb0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1530\/eje.0.1460743","article-title":"The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism","volume":"146","author":"Carella","year":"2002","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP.12.2.231_bb0045","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/BF03345087","article-title":"Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study","volume":"25","author":"Mazziotti","year":"2002","journal-title":"J Endocrinol Invest."},{"key":"10.4158\/EP.12.2.231_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4158\/EP.11.2.135","article-title":"Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C","volume":"11","author":"Lin","year":"2005","journal-title":"Endocr Pract."},{"key":"10.4158\/EP.12.2.231_bb0055","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.2004-0627","article-title":"Clinical review 169: interferon-alpha-related thyroid disease; pathophysiological, epidemiological, and clinical aspects","volume":"89","author":"Carella","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.12.2.231_bb0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","article-title":"Administration of thyroxine in treated Graves\u2019 disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism","volume":"324","author":"Hashizume","year":"1991","journal-title":"N Engl J Med."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20401478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20401478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/EW9CE138D1825N3K.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:46:05Z","timestamp":1761515165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20401478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1530891X20401478"],"URL":"https:\/\/doi.org\/10.4158\/ep.12.2.231","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyrotoxicosis During Pegylated Interferon Therapy in a Patient With Chronic Hepatitis C Virus","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.12.2.231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}